Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017 Nov 08; 9(415).
View in:
PubMed
subject areas
Animals
Antibodies
Antineoplastic Agents
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
CTLA-4 Antigen
Disease Models, Animal
Extracellular Matrix
Extracellular Matrix Proteins
Fibrinolysin
Genetic Engineering
Heparin
Immunity
Immunotherapy
Lymphocytes, Tumor-Infiltrating
Melanoma, Experimental
Mice, Inbred C57BL
Peptides
Placenta Growth Factor
Treatment Outcome
authors with profiles
Jeffrey Hubbell
Melody Swartz